Chembio Diagnostics to Report Fourth Quarter and Full Year 2021 Financial Results on March 3, 2022
February 17 2022 - 4:05PM
Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care
diagnostics company focused on infectious diseases, announced today
that it will release financial results for the fourth quarter and
full year 2021 after the close of trading on Thursday, March 3,
2022.
The company’s management team will host a
corresponding conference call beginning at 4:30 p.m. Eastern Time
on March 3, 2022. Investors interested in listening to the
conference call may do so by dialing 888-506-0062 from the US or
973-528-0011 from outside the US and providing Entry Code: 516973
or by accessing www.chembio.com/investors/calendar-of-events/. A
replay of the call will be available by dialing 877-481-4010 from
the US or 919-882-2331 from outside the US using passcode 44503 or
by accessing www.chembio.com/investors/calendar-of-events/.
About Chembio DiagnosticsChembio is a leading
diagnostics company focused on developing and commercializing
point-of-care tests used for the rapid detection and diagnosis of
infectious diseases, including sexually transmitted disease, insect
vector and tropical disease, COVID-19 and other viral and bacterial
infections, enabling expedited treatment. Coupled with Chembio’s
extensive scientific expertise, its novel DPP technology offers
broad market applications beyond infectious disease. Chembio’s
products are sold globally, directly and through distributors, to
hospitals and clinics, physician offices, clinical laboratories,
public health organizations, government agencies, and consumers.
Learn more at www.chembio.com.
Investor contact:
Philip TaylorGilmartin Group(415)
937-5406investor@chembio.com |
|
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Apr 2023 to Apr 2024